Stagg et al. 16 demonstrated that anti-ErbB-2 mAb therapy of ErbB-2 tumors induced sustained tumor regression in syngeneic immunocompetent mice but failed to have an effect in mice depleted of CD8α+ cells. This evidence concerns the gene CD8A and neoplasm.